Aarhus University Hospital

The Dermatology and Venereology department at Aarhus University Hospital is pioneering new diagnostic platforms and therapeutic delivery systems for skin disorders, with a focus on assessing the safety of innovative topical agents.

• Topical JAK inhibitor safety assessment
• Proof‑of‑concept studies for novel skin therapies
• Development of advanced monitoring tools for dermatologic patients

This work bridges cutting‑edge technology with patient care, aiming to bring faster, more precise treatment options to those affected by rare skin diseases.

Researchers are exploring immune‑modulating strategies for conditions such as bullous pemphigoid, targeting cytokine pathways to reduce disease activity and improve quality of life.

• IL‑13 inhibition in bullous pemphigoid
• Immune profiling for cutaneous T‑cell lymphoma
• Safety evaluation of immunomodulatory topical treatments

The program emphasizes collaboration with immunology experts to translate laboratory insights into effective clinical interventions.

Clinical investigations at the site focus on rare skin and connective tissue diseases such as cutaneous T‑cell lymphoma and mycosis fungoides, seeking to expand therapeutic options and refine disease management.

• Novel treatment evaluation for cutaneous T‑cell lymphoma
• Proof‑of‑concept trials for bullous pemphigoid therapies
• Patient‑centered approaches to mycosis fungoides care

By integrating patient experiences with scientific advances, the department aims to enhance outcomes for individuals living with these challenging conditions.